scholarly journals Current status of uric acid level in treated hypertensive patients

2013 ◽  
Vol 37 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Minako Sakaki ◽  
Takuya Tsuchihashi
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Current Status ◽  
Hypertensive Patients

scholarly journals A study of serum uric acid level in hypertensive patients

2019 ◽  
Vol 5 (2) ◽  
pp. 16
Author(s):  
Baruah Rumi ◽  
Baruah Bhaskar ◽  
Baruah SK ◽  
Saikia Nirmita
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients

scholarly journals SIGNIFICANCE OF LOWERING SERUM URIC ACID LEVEL IN HYPERTENSIVE PATIENTS

2018 ◽  
Vol 5 (45) ◽  
pp. 3178-3182
Author(s):  
Barochia D.V ◽  
Bhattacharyya P.C ◽  
Manabendra Nayak
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients

scholarly journals Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients

Hypertension ◽  
2013 ◽  
Vol 62 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Jesse Dawson ◽  
Panniyammakal Jeemon ◽  
Lucy Hetherington ◽  
Caitlin Judd ◽  
Claire Hastie ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients ◽  
Long Term Mortality

scholarly journals Serum uric acid level among diabetic, hypertensive and diabetic-hypertensive patients attending specialist hospital Sokoto

2020 ◽  
Vol 10 (1) ◽  
pp. 109-117
Author(s):  
Yale Bala Malam ◽  
Yeldu Muhammed Haruna ◽  
Dallatu Kabiru Muhammed ◽  
Danjuma Abubakar
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients

scholarly journals Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
O Obertynska
Keyword(s):  
Metabolic Syndrome ◽  
Weight Loss ◽  
Uric Acid ◽  
Glucose Tolerance ◽  
Uric Acid Level ◽  
Weight Reduction ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients ◽  
Metabolic Syndrome Components

Abstract Purpose Obesity is independently associated with blood pressure (BP) and weight loss is recommended for BP reduction in overweight hypertensive individuals. However, the challenge remains to find an appropriate approach for weight reduction to influence BP status. The aim was to evaluate the effects of orlistat (O) and metformin (M) on BP and metabolic homeostasis in obese hypertensive patients (P). Methods 106 P (mean body mass index (BMI) 34.2 kg/m2, waist circumference (WC) 104 cm) were included in the study. All followed a diet (D) for 3 month, after that 52 P started on M (1000 mg/day) and 52 on O treatment (360 mg/day) for 6 month. Anthropometry, metabolic profile, including lipids and oral glucose tolerance test with insulin, uric acid, serum creatinine, calculated GFR were performed at baseline and after 3, 6, 9 months. Homeostatic model assessment HOMA-R was calculated for insulin resistance. At baseline and after 9 months P underwent clinic and 24-hour BP measurements. Results At baseline was an excellent correlation between BMI and HOMA-R (r=0.45, P<.01), BMI and uric acid (r=0.31, P<.05). Also asymptomatic hyperuricemia was observed in 24.9%, dyslipidemia in 43.1%, impaired glucose tolerance in the 21% and chronic kidney disease in 9.0% P. 29% of the P had >3 metabolic syndrome components. There was no significant reduction in BMI (−0.9±0.1 kg/m2) and BP after 3 month of D in the whole group. The reduction of BMI was significant in both groups after 6 months of pharmacological treatment (P<0.01 for O and P <0.05 for M) but was significantly greater in group O than in group M (−0.61±0.3 versus −0.32±0.2 kg/m2, P<.01). Treatment with O produced a 4.16% reduction in weight (101.0±8.0 vs. 95.3±7.1 kg, P<.01) and this reduction was more significant than the reduction produced by M (4.69 vs. 2.42%, P<.01). There were also greater reductions in WC with O therapy compared to M (P <.05). We also found a slight, though not significant, improvement in HOMA-R in both groups. BP decreased more in O than in M (SBP −6.7±7.1 vs. −3.2±5.7 mmHg and DBP −6.4±6.2 vs. −2.2±8.1 mmHg, P<.01 for both). The O group had significantly greater reductions in total cholesterol and low-density lipoprotein cholesterol (P<.01 for both). Moreover, we found significant reduction of serum uric acid level after O therapy in comparison with M (P<.01). Conclusions 29% of the obese hypertensive patients had >3 metabolic syndrome components. Abdominal obesity was the most common, followed by dyslipidemia, asymptomatic hyperuricemia and impaired glucose tolerance. Lifestyle program with diet alone wasn't enough for a reduction in weight and BP. Weight-loss program with orlistat is more effective than with metformin and leads to better BP control in obese hypertensive individuals. The weight reduction by O is associated with lipid-lowering effect and reduction of serum uric acid level, what can result in the reduction of cardiovascular risk. FUNDunding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): National Medical University

A STUDY OF SERUM URIC ACID LEVELS IN PREECLAMPSIA

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Sushma Goad ◽  
Anita Verma ◽  
Subhash Chandra
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Control Group ◽  
Age Group ◽  
Hypertensive Disorders Of Pregnancy ◽  
Level Elevation ◽  
The Mean

Background: To Study Serum Uric Acid level elevation in Hypertensive Disorders of Pregnancy. Methods: 50 Patients diagnosed as having Pre-eclampsia with age between 18-37 years and 50 controls with similar age group. Results: The mean serum uric acid level in control group was 3.41 ± 0.62 and in patient 7.01 ± 0.58 which was statistically significant (p =0.001). Conclusion: Serum uric acid levels were significantly higher in preeclampsia could be a useful indicator of fetal complication in preeclampsia patients. Keywords: serum uric acid, preeclampsia, laboratory.

Sign in / Sign up

Export Citation Format

Share Document